Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baxter Runs With Cheetah Medical In $230M Deal

Executive Summary

Baxter International is buying Israeli company Cheetah Medical in a $230m deal. The acquisition expands Baxter’s portfolio of medication delivery products.

You may also be interested in...



Baxter Reports $45M Boost From COVID-19 Demand In Q1

The COVID-19 pandemic has increased demand for products from all of Baxter’s businesses except its advanced surgery division. Overall, the diversified company’s global sales were up 8% in the first quarter.

CEO Pay Packages Expand in India But Ratio To Employee Earnings Hurts

Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.

Teva UK Enters Erectile Dysfunction Category With First Ever Rx-To-OTC Switch

Teva UK's first Rx-to-OTC switch is a UK Viagra Connect sildenafil competitor under the Liberize brand. Priced around 25% lower than the market leader, Teva's new brand must also compete with Perrigo's white label and Dr Reddy's Almus branded alternatives within the country's growing erectile dysfunction category. 

Topics

Related Companies

UsernamePublicRestriction

Register

MT125615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel